CKD Treatment: Addressing Kidney and Cardiometabolic Outcomes Part 3: GLP1 Receptor Agonists

Register/log in to view the handouts.
How to navigate the module?

The cardiovascular benefits of GLP1 RAs have been well characterized in several large cardiovascular outcome trials. The benefits of secondary kidney outcomes in those with diabetes have been observed in these trials. In this module, we will review current evidence supporting the benefits of GLP-1 RAs in the patients with kidney disease. We will also review current clinical guidelines and recommendations for their use and discuss medication and patient-specific efficacy and safety considerations when using them in people with type 2 diabetes and chronic kidney disease.

By the end of this module, learners will be able to:

  1. Summarize the evidence to support use of GLP1RAs for slowing CKD progression, reducing albuminuria and cardiovascular risk
  2. Determine the  goals of therapy for critical effectiveness and safety endpoints for use of GLP1RAs in patients with kidney disease
  3. Design care plans to facilitate pharmacoequity for the use of GLP4RAs by ensuring access and optimal use across populations
  4. Using a patient case:
    • Apply guideline-directed medication therapy (or evidence-based medication practice) for GLP1RAs use to reduce CKD progression, albuminuria and cardiovascular risk
    • Create a monitoring plan for GLP1RAs safety and effectiveness  in a patient with CKD
    • Describe potential complications of GLP1RAs in patients with CKD stages 4-5

Time: 30 minutes


The following planners and presenters have disclosed a financial relationship with an ineligible company:

  • Katie Cardone, PharmD, BCACP, FNKF, FASN, FCCP - Grants/Research Support [Merck & Co], Consultant [Vifor, Otsuka], Honorarium [Pharmacy Times]
  • Calvin Meaney, PharmD, BCPS - Speaker's Bureau [GSK], Consultant [GSK, Wolters-Kluwer (Lexicorp)]
  • Joshua Neumiller, PharmD, CDCES, FADCES, FASCP, Speaker's Bureau [Dexcom], Consultant [Bayer, Eli Lilly, Sanofi], Editorial Board: Associate Editor [Diabetes Spectrum]
  • Wendy St. Peter, FCCP, FASN, FNKF - Consultant [GSK]

There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.

All relevant financial relationships have been mitigated.

Accreditation Details

In support of improving patient care, this activity is planned and implemented by The National Center for Interprofessional Practice and Education Office of Interprofessional Continuing Professional Development (OICPD). The OICPD is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credit for learning and change.

Jointly Accredited Provider logoIPCE Credit logo

Physicians: The National Center for Interprofessional Practice and Education designates this live activity for . 5 hours AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with their participation.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.

Nurses: Participants will be awarded .5 contact hours of credit for attendance in this module.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.

Pharmacists: This activity is approved for .5 contact hours. UAN: JA4008105-9999-23-028-H01-P.

IPCE: This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credits for learning and change.